-
Hackensack Meridian John Theurer Cancer Center Treats its First Patient in Innovative Cell Therapy Clinical Trial
Researchers at Hackensack Meridian John Theurer Cancer Center — part of the National Cancer Institute-designated Lombardi Comprehensive Cancer Center at Georgetown University —treated its first patient at the Center in a cutting-edge phase I clinical trial of LYL845, a novel cellular therapy under evaluation for advanced melanoma and other select solid tumors. A type of tumor-infiltrating lymphocyte (TIL) therapy, LYL845 is custom-made from a patient’s cells and designed to help the immune system find and kill cancer cells.
Category: Lombardi Stories
-
John Theurer Cancer Center Physician Co-Authors Clinical Research on Innovative Oral Leukemia Therapy
Researchers at Hackensack Meridian’s John Theurer Cancer Center are part of a published Phase 3 study reporting on the equivalent safety and effectiveness in the oral treatment of blood cancers, such as myelodysplastic syndrome and/or chronic myelomonocytic leukemia, to its previously inpatient, intravenous treatment counterparts. John Theurer Cancer Center is part of the NCI-designated Lombardi Comprehensive Cancer Center at Georgetown University.
Category: Lombardi Stories
-
John Theurer Cancer Center Physician Co-Authors Clinical Research on mRNA Vaccine Intervention Benefits in High-Risk Melanoma
Researchers at Hackensack University Medical Center’s John Theurer Cancer Center (JTCC), a part of the NCI-designated Lombardi Comprehensive Cancer Center at Georgetown University, reported on a novel mRNA vaccine’s delivering improved survival rates in Stage IIIB and IV (metastatic) skin cancer, as part of an ongoing joint-study.
Category: Lombardi Stories
-
Tumor Biology Program Student Advocates for More Deaf and Hard-of-Hearing Scientists
Megan Majocha (G’24) finds herself on a dual mission. As a PhD student conducting breast cancer research, she wants to contribute to the understanding of what drives a specific type of cancer to spread. But as a scientist in the making, Majocha, who is deaf, also wants to make sure the path to becoming a researcher is smoother for kids who grew up just like her.
Category: Lombardi Stories
-
Drug Found to be Effective in Difficult to Treat Autoimmune Blood Disorder
Category: News Release
-
Hands-on Healing
Category: Lombardi Stories
-
Ralph Lauren Corporate Foundation Makes Gift to Address Disparities in Cancer Care
Category: Lombardi Stories
-
St. Baldrick’s Event Organizers Motivated by Personal Connections with Pediatric Cancer
Category: Lombardi Stories
-
Georgetown Alumnus and Longtime Georgetown Lombardi Supporter Drives Research Forward on Rare Pediatric Cancers
Category: Lombardi Stories
-
Health Informatics and Data Science Symposium Goes Virtual
Category: Lombardi Stories
